* Chemomab Therapeutics Ltd CMMB.OQ CMMB.O is expected
to show
no change in quarterly revenue when it reports results on
November 14 for the period ending September 30 2024
*
* LSEG's mean analyst estimate for Chemomab Therapeutics
Ltd is
for a loss of 1 cent per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Chemomab
Therapeutics Ltd is $9.00, above its last closing price
of $1.57.
This summary was machine generated November 12 at 13:55 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)